SCHEMBL25972146

SCHEMBL25972146

CC(=O)c1cc(O)n(Cc2ccccc2)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 1/20 0.47
GRN P28799 2/20 0.47
SORT1 Q99523 2/20 0.47
POLB P06746 3/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
P2RY14 Q15391 2/20 0.45
BRD4 O60885 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 2/20 0.44
TSHR P16473 1/20 0.44
GAA P10253 1/20 0.43
MARS1 P56192 1/20 0.42
SLC16A3 O15427 1/20 0.41
NPC1 O15118 1/20 0.41
PTGS2 P35354 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15056101 0.87 P2RY14 (0.53) MALT1GRNSORT1POLBKMT2A
SCHEMBL17324801 0.84 AURKA (0.52) MALT1GRNSORT1POLBKMT2A
SCHEMBL25972441 0.82 CYP19A1 (0.44) POLBKMT2A
SCHEMBL13373558 0.81 SMN1; SMN2 (0.58) POLBKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL25972165 0.80 P2RY14 (0.44) P2RY14TP53
SCHEMBL25972032 0.80 AURKA (0.42) KMT2AMEN1P2RY14SMN1; SMN2MARS1
SCHEMBL2845945 0.78 POLB (0.50) GRNSORT1POLBKMT2AMEN1
SCHEMBL8192476 0.78 KMT2A (0.58) POLBKMT2AMEN1SMN1; SMN2LMNA
SCHEMBL2208700 0.77 GRN (0.46) MALT1GRNSORT1POLBKMT2A
SCHEMBL12402397 0.77 PTGS2 (0.48) GRNSORT1POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718612-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease RIPK1, RIPK2, RIPK4 MALT1 2349/4885GRN 1091/4885SORT1 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.